These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23422874)

  • 1. Cardiovascular disease prevention: matching evidence-based algorithms with individualized care.
    Madanieh R; Hasan RK; Anusionwu OF; Blumenthal RS; Blaha MJ
    Clin Pharmacol Ther; 2013 Apr; 93(4):321-3. PubMed ID: 23422874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).
    Samson RH; Nair DG
    Semin Vasc Surg; 2011 Sep; 24(3):172-9. PubMed ID: 22153029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prevention cardiovascular disease: better than drugs.
    Pippin JJ
    Arch Intern Med; 2010 Nov; 170(20):1860-1; author reply 1861. PubMed ID: 21059984
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease.
    Thanassoulis G; Williams K; Altobelli KK; Pencina MJ; Cannon CP; Sniderman AD
    Circulation; 2016 Apr; 133(16):1574-81. PubMed ID: 26945047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Statins with a perspective of lifelong therapy].
    Ertaş FS
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins for the primary prevention of cardiovascular events in elderly patients: a picture from clinical practice without strong evidence from clinical trials.
    Trifirò G; Alacqua M; Corrao S; Tari M; Arcoraci V
    J Am Geriatr Soc; 2008 Jan; 56(1):175-7. PubMed ID: 18184214
    [No Abstract]   [Full Text] [Related]  

  • 11. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
    Spatz ES; Canavan ME; Desai MM
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):41-8. PubMed ID: 20031811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM
    J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hyperlipidemia in older adults.
    Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The JUPITER trial: a new approach in primary prevention].
    Güleç S
    Turk Kardiyol Dern Ars; 2009 Apr; 37 Suppl 4():18-26. PubMed ID: 19553758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are statins effective in high-risk primary prevention?
    Dentali F; Guasti L
    Arch Intern Med; 2010 Dec; 170(22):2042-3; author reply 2043-4. PubMed ID: 21149769
    [No Abstract]   [Full Text] [Related]  

  • 17. [The JUPITER study: critical review of final results].
    Urbinati S; Romanazzi S; Gambetti S
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):28S-32S. PubMed ID: 21298859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin therapy for primary prevention of cardiovascular disease.
    Taylor FC; Huffman M; Ebrahim S
    JAMA; 2013 Dec; 310(22):2451-2. PubMed ID: 24276813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
    O'Keefe JH; Carter MD; Lavie CJ; Bell DS
    Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of evidence-based therapy for the prevention of cardiovascular events among older people.
    Castelino RL; Chen TF; Guddattu V; Bajorek BV
    Eval Health Prof; 2010 Sep; 33(3):276-301. PubMed ID: 20801973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.